Qbtech builds clinically researched software and objective ADHD tests to support diagnosis, treatment monitoring and improved outcomes for patients. Their products combine objective data with clinical expertise to make ADHD evaluation faster, more consistent and evidence-based.

Products include QbTest (in-clinic) and QbCheck (remote/home testing). Qbtech’s technology is peer-reviewed in more than 40 clinical studies and is recommended in clinical guidance, including NICE diagnostic guidance for ADHD in children and young people.

Founded from clinical research and lived experience of ADHD, Qbtech has developed FDA-cleared testing technology and expanded globally. The company emphasises a technology-first approach to combine subjective and objective data, reducing diagnostic delay and improving diagnostic accuracy.

Headquartered in Stockholm, Qbtech also operates in the USA, UK and Germany. The company states a mission to improve the lives of people with ADHD, focusing on accessibility, neurodiversity-friendly design and supportive workplace culture. Qbtech works with clinicians, partners and health systems to scale ADHD care and clinical research.